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A B S T R A C T   
Objective: To estimate the incidence and recurrence of breast cancer (BC) in patients with vulvovaginal atrophy 
(VVA) treated with ospemifene and matched untreated VVA patients using real-world data. 
Study design: Retrospective matched cohort study. 
Main Outcome Measures: VVA patients were identified from the 2011–2018 US MarketScan® insurance 
claims database. For incidence, ospemifene-treated VVA patients without evidence of BC prior to index treat-
ment were matched to two untreated VVA controls similarly without history of BC on age, index VVA year, 
geographic region, Charlson Comorbidity categories, and follow-up time. BC after the index treatment was 
identified by BC diagnosis codes, mastectomy, chemotherapy, or radiation procedure. Incidence rate, rate ratio 
(RR) and their 95 % confidence intervals (CI) were calculated. The process was repeated to estimate BC re-
currence in patients with a history of BC in 1:1, 1:2 and 1:3 matches. 
Results: 1728 ospemifene users and 3456 untreated patients met the inclusion and matching criteria for asses-
sing incidence. The average number of days for which ospemifene was supplied was 314 (standard deviation 
[SD] = 340). Average follow-up time from index treatment was 937 days (SD = 392) for treated patients and 
915 days (SD = 396) for controls. BC incidence rates per 1000 person-years was 2.03 (95 % CI: 1.06−3.91) for 
treated patients and 3.53 (95 % CI: 2.49−4.99) for controls (RR = 0.58, 95 % CI: 0.28−1.21). No difference in 
recurrence was observed between ospemifene-treated and matched untreated patients. Ten (32.3 %) treated vs. 
25 (40.3 %) controls in the 1:2 matched analysis had a recurrence. 
Conclusion: No differences were observed in the BC incidence and recurrence rates in ospemifene users com-
pared with matched controls.   
1. Introduction 
Vulvovaginal atrophy (or VVA), part of the genitourinary syndrome 
of menopause (GSM), is a condition that develops in an estrogen-defi-
cient setting that affects peri-and post-menopausal women causing 
several distressing urogenital symptoms including dryness, reduced 
lubrication, itching, burning, irritable bladder symptoms and painful 
intercourse [1,2]. An estimated 50 % of postmenopausal women will 
experience symptoms of VVA [1], greatly impacting their quality of life 
[1,3]. Treatment for VVA consist of over the counter lubricants, 
moisturizers or vaginal prescription estrogen therapies, and prescrip-
tion dehydroepiandrosterone (DHEA) [3–5], however their use is re-
ported in less than half of the VVA patients [3]. A patient preference 
survey found that of those reporting use of treatments, only a quarter of 
patients reported use of vaginal estrogen therapies, citing long-term 
safety concerns including breast cancer (BC) [3]. 
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Physicians hesitate to prescribe vaginal estrogen therapies in BC 
survivors with VVA due to a fear of increased cancer recurrence and 
possible interferences with tamoxifen [6]. As such, estrogen therapy 
was only prescribed by 21 % of physicians in one study [6]. Even when 
prescribed, this survey found 43 % of women refuse to take it, with 
another 36.5 % asking for reassurance prior to use. Despite its perceived 
efficacy over non-hormonal treatments, vaginal estrogen therapy is 
mostly a second-line treatment after moisturizers and lubricants; even 
with an absence of documented benefit of moisturizers and lubricants 
for the cellular and pH changes needed to reconstitute normal phy-
siology [7]. A recently published meta-analysis in The Lancet 2019 
found that across 128,435 cases with invasive BC and 366,965 patients 
without BC, there was significant excess risk of BC associated with >  
1 year of oral or transdermal estrogen and estrogen-progestogen hor-
mone therapy use [8]. Therefore, VVA may pose a serious problem for 
BC survivors, as there is no clear safe and effective treatment option. 
Ospemifene (OSPHENA®, SENSHIO) is a selective estrogen-receptor 
modulator (SERM) approved by the FDA in 2013 for the treatment of 
moderate to severe dyspareunia, a symptom of VVA, due to menopause 
[9]. Ospemifene is also approved in Europe for the treatment of mod-
erate to severe symptomatic VVA in postmenopausal women who are 
not candidates for local vaginal estrogen therapy [10]. Ospemifene 
evolved from a tamoxifen metabolite and is a weak antiestrogen on the 
breast tissue. Though the clinical trial program did not specifically 
study ospemifene (60 mg) in women with BC [9], clinical studies since 
its approval have indicated no increased risk for BC or breast-related 
safety concerns among patients receiving ospemifene [11–16]. This 
study aimed to assess the risk of BC incidence or recurrence and expand 
the evidence base of ospemifene safety regarding BC [9]. 
2. Methods 
2.1. Study objectives 
The overall study objective was to estimate the incidence of BC in 
ospemifene users in a real-world setting. This study assessed the in-
cidence rate of BC among postmenopausal women with VVA without a 
history of BC treated with ospemifene to matched patients without any 
VVA-related treatments. A secondary analysis explored recurrence of 
BC among postmenopausal women with VVA with history of BC after 
ospemifene treatment compared with an untreated, matched cohort. 
2.2. Study design and data source 
This retrospective, observational study was conducted using the 
2011–2018 IBM® MarketScan® Commercial and Medicare supplemental 
database, one of the largest collections of individual-level, de-identi-
fied, healthcare claims data from employers, health plans, hospitals and 
Medicare and Medicaid programs in the US [17]. The database includes 
inpatient and outpatient episode diagnoses (both ICD-9-CM and ICD-10- 
CM), procedures (CPT and HCPCS) and prescription records (retail and 
mail-order). Available prescription data include the National Drug Code 
(NDC), J-codes and the dispensed quantity supply [17]. 
2.3. Study populations 
2.3.1. Incidence of breast cancer 
The primary analysis calculated the BC incidence in VVA patients 
treated with ospemifene versus untreated matched controls. The study 
included women with a diagnosis of VVA, defined as > 45 years old and 
a diagnosis of postmenopausal atrophic vaginitis (ICD-9 code 627.3, 
ICD-10 code N95.2) or > 55 years and a diagnosis of atrophy of vulva 
(ICD-9 code 624.1, ICD-10 code N90.5) or dyspareunia (ICD-9 code 
625.0, ICD-10 code N94.1). Women with BC or a history of BC were 
excluded from the study. BC was defined as 1) two BC diagnoses in 
outpatient settings in non-consecutive days within 90-day period, 2) 
mastectomy, 3) BC diagnosis with chemotherapy procedure, or 4) BC 
diagnosis with radiation procedures. History of BC was assessed using 
ICD-9/10 codes V10.3, Z853. The ospemifene cohort were patients 
treated with ospemifene and no other VVA-related treatment after the 
first diagnosis of VVA. Untreated controls were VVA women without 
any prescribed VVA-related treatment. Data for over-the-counter 
treatments for VVA were not available from this data source and were 
therefore not considered. 
Matching methodology ensured treated cases and controls had si-
milar baseline characteristics and comorbid conditions. Each ospemi-
fene-treated patient was randomly matched to two controls in a two- 
step process. Step 1 matched each treated woman with any number of 
controls on age at index VVA date, year of index VVA, US region, and 
follow-up month from index VVA to last record. The index treatment 
date was copied from the treated to the matched controls as pseudo- 
index treatment date. Only patients and suitable matches with 1) 
≥1 year of pharmacy and medical enrollment prior to index VVA date 
and 2) ≥1 year after the index treatment date, and 3) without evidence 
of BC (defined above) before treatment date were included for the next 
match step. 
Step 2 randomly matched with two untreated controls on age at 
index VVA date, Charlson Comorbidity Index (CCI) categories at index 
VVA date [18], year of index VVA, US region, and follow up month 
from index VVA to the last record. 
While the matching process matched on VVA index date, incidence 
analyses were based on treatment index dates. Incident BC cases after 
treatment index date for both cases and controls were defined using the 
BC definition stated above. Follow-up times ended at either cancer 
onset date or last record in the database, whichever occurred first. 
2.3.2. Recurrence of breast cancer 
A secondary analysis assessed BC recurrence in VVA patients in BC 
remission. The study population was female with a diagnosis of VVA 
and evidence of BC in remission, defined as a diagnosis of confirmed BC 
or dispensing of ≥6 months of aromatase inhibitor (AI) 180 days prior 
to initiating ospemifene for patients receiving ospemifene. An ospemi-
fene-treated group and an untreated-group were created using two 
steps. Step 1 selected all available cases and controls based on the above 
patient identification criteria. Controls were assigned pseudo-index 
dates based on their VVA index date plus the additional day gap be-
tween confirmed BC diagnosis or use of last AI to first ospemifene 
treatment in the treated patients. Among the 58 treated patients, there 
were 54 different day gap periods; therefore, each control patient had 
54 potential pseudo-index dates. Only cases and controls with ≥1 year 
of pharmacy and medical enrollment prior to and after treatment- or 
pseudo-index dates and no evidence of receiving chemotherapy or other 
BC treatments within 180 days of the index treatment date or pseudo- 
index date were kept for the next matching process. Step 2 randomly 
selected matched controls in 1:1, 1:2, and 1:3 ratios on age, index 
treatment year, region and CCI score at index treatment date. The order 
of the 54 pseudo-index dates followed a random variable from a uni-
form distribution for the matching process. Controls did not have a 
single, definite pseudo-index date until matching was complete. In the 
analysis, the index date for cases was the date of first ospemifene 
treatment, the pseudo-index date for control was their VVA index 
date + the day gaps from matched case patient. The recurrence rate 
was assessed after index date for both cases and controls. 
Though combination of tamoxifen and another AI combination has 
been found to be ineffective in clinical trials [19], the study explored its 
use in breast cancer recurrence cohort. 
2.4. Statistical analyses 
Descriptive statistics were used to summarize the demographic 
characteristics of the incidence cohorts. Continuous variables were 
described with mean, median, and standard deviation (SD). Categorical 
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variables were described with frequency and percentage. The BC in-
cidence rate was calculated using total incident cases divided by total 
follow-up time from index treatment date until first observed BC event 
or the end of follow-up for each cohort. The rate ratio was calculated as 
the incidence rate in treated cohort over control cohort. The corre-
sponding 95 % confidence intervals (CI) for BC in each cohort were 
calculated using Poisson regression with log link function without ad-
justing covariates. Time to BC onset was estimated using Kaplan-Meier 
(KM) analyses. The difference in survival probabilities between treated 
and untreated cohorts were assessed using long-rank tests. A life-table 
with 6-month intervals was constructed for the incident BC cases. A chi- 
squared test was used to test the association between BC recurrence and 
treatment because of the small sample size. 
All analyses were performed using SAS version 9.4 (SAS Institute, 
Cary, NC). 
3. Results 
3.1. Incidence of breast cancer 
1,602,233 patients with ≥1 claim for VVA were identified in the 
MarketScan® database between 1 January 2011 and 31 December 2018. 
From these patients, 3157 patients met our ospemifene-treated case 
definition and 157,269 patients met our untreated control definition. 
After the first step matching, 3057 cases and 32,244 controls met the 
previously described criteria. After the second matching which required 
each case to have exactly 2 matched controls on CCI and no history of 
BC prior to treatment index date, a total of 1728 cases and 3456 con-
trols were included for further analysis. 
Included patients had a mean age of 57.8 (SD: 4.0). No statistically 
significant differences across demographic variables were observed. 
Average days ospemifene supplied was 313.7 days (SD = 340.3). The 
median follow-up time from index VVA to end of the follow-up was 969 
days (31.8 months) (IQR: 659.5–1326.5 days) for cases and 970 days 
(31.9 months or 136.7 Weeks) (IQR: 656.0–1323.0) for controls 
(p = 0.91). The median follow-up days from treatment index to the end 
of the follow-up differed by 22 days between cases and controls; cases 
had a median 884 days (IQR: 597.0–1204.5) compared to a median 906 
days (IQR: 616.5–1244.0) for controls (p = 0.05). This difference is 
likely clinically insignificant, and an artifact powered by a large sample 
size. 
There was no statistically significant difference between incidence 
of BC among ospemifene-treated cases and the untreated controls; 9 
cases (0.52 %) and 32 controls (0.93 %) had a BC diagnosis on or after 
ospemifene treatment index date (p = 0.121). BC incidence rate was 
2.03 per 1000 person-years (PY) (95 %CI: 1.06–3.91) in ospemifene- 
treated patients and 3.53 per 1000 PY (95 % CI: 2.49–4.99) in control 
group. The incidence rate ratio of 0.58 (95 % CI: 0.28–1.21) indicates a 
lower incidence of BC among ospemifene-treated patients, although not 
statistically significant (Table 1). A similar trend (2.83 per 1000 PY in 
the treated group vs. 3.51 in the control group) was observed after the 
first matching step of cases to controls. 
The KM curves of BC incidence further demonstrated lower in-
cidence in ospemifene-treated patients, although not statistically sig-
nificant (log-rank p = 0.137); note the KM median was not reached 
(Fig. 1). For ospemifene-treated patients, the BC-free rate at 60 months 
was 99.2 % compared to 98.4 % in untreated patients. KM curves were 
similar when cases were matched to many controls. With the given 
sample size in each cohort and median follow-up time, the study had a 
70 % of power to detect ≥2 hazard ratio between ospemifene and 
controls, a threshold commonly used to assess the safety of new pro-
ducts, and an 81.7 % power to detect ≥2.2 hazard ratio, both at 5% 
significance level. 
A life-table at six-month post-treatment follow-up intervals de-
monstrated no increased incidence in BC between the two groups 
during the follow-up period (Table 2 a and b). Only three of the nine 
patients were diagnosed with BC while receiving ospemifene treatment, 
whereas more frequent diagnoses of BC occurred in the untreated group 
over time, including 21 diagnoses in the first 18 months of follow-up 
(Table 2a). 
3.2. Recurrence of breast cancer 
After the first matching step, 58 patients with VVA treated with 
ospemifene had a history of BC and 14,657 patients with untreated VVA 
had a history of BC. 17 of 58 (29 %) ospemifene treated patients and 
10,937 of 14,657 (75 %) controls had BC recurrence. After 1:1 
matching at the second matching step, 46 of 58 ospemifene patients had 
1 matched control and there was no observed increase in risk of BC 
recurrence in patients treated with ospemifene. Additional analyses 
were conducted with cases further matched 1:2 (each case must have 2 
matched controls) and 1:3 with controls; each analysis demonstrated no 
increased risk in BC recurrence (Table 3). Of note, in the 1:1 matched 
cohort, only one treated patient and one control patient received 
treatment with tamoxifen and another AI combination therapy, thereby 
limiting any risk bias associated with AI and tamoxifen combinations. 
4. Discussion 
This study investigated the incidence and recurrence of BC among 
patients with VVA treated with ospemifene using MarketScan® database 
from 2011 to 2018. The use of ospemifene in women with BC was not 
studied in its clinical development program and is currently advised 
against in women with known or suspected BC or with a history of BC 
[9]. In Europe, ospemifene can be prescribed to cancer survivors, if they 
have completed their active/adjuvant treatment [10]. Preclinical/an-
imal model studies showed ospemifene had no effect on normal breast 
tissue and subsequent analyses using clinical data have demonstrated 
no increased risk in BC-related outcomes [12,13,15,20,21]. Therefore, 
the safety of ospemifene use in women with BC, BC survivors or women 
at risk for BC is of interest to both physicians and patients. 
Since its 2013 approval, clinical studies have reported results in 
Table 1 
Incidence rate of breast cancer per 1000 patients per follow-up year and treatment year.      
Crude Analysis Treated group 
(N = 1728) 
Untreated Group 
(N = 3456) 
Rate Ratio  
Assessment per follow-up year 
Total number of patients with breast cancer diagnosis any time on or after treatment index date (%) 9 (0.52) 32 (0.93)  
Total number of treatment years between index date and follow-up end date 4428 9074  
Incidence rate of breast cancer per 1000 patients per follow-up year (95 % CI) 2.03 (1.06−3.91) 3.53 (2.49−4.99) 0.58 (0.28−1.21) 
Assessment per treatment year 
Total number of patients with breast cancer diagnosis any time while on treatment (only use first continuous 
treatment - 90-day gap) 
3 –  
Total number of treatment years between treatment start and treatment end 1420 –  
Incidence rate of breast cancer per 1000 patients per treatment year (95 % CI) 2.11 (0.44−6.18)   
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support of ospemifene use in women with BC or suspected history 
[11–16]. Most recently, a 2019 meta-analysis of randomized trials on 
VVA treatment found that the incidence of BC was not significantly 
different between patients receiving ospemifene and those receiving 
placebo [11]. The longest of the studies included, a 52-week follow-up 
investigation (after a 12-week treatment period) of the long-term safety 
of ospemifene in the treatment of hysterectomized patients with VVA, 
mean age 59.4, found that in 301 subjects there were no instances of BC 
[12]. A study in postmenopausal women, mean ages 57.7–58.4, with a 
uterus similarly found no instances of BC after 52 weeks of ospemifene 
treatment [13]. In both these studies, the patients were approximately 
the same age as women in our study. 
To the authors’ knowledge, this is the first study to utilize a large, 
national database to assess the relation between BC incidence, recur-
rence and ospemifene treatment. With median follow-up data of over 
126 weeks and 1728 cases, this study found that there was a no sig-
nificant difference in incidence of BC in patients with VVA treated with 
ospemifene versus matched untreated patients. Additionally, there was 
no increased recurrence of BC in patients in remission treated with 
ospemifene versus untreated. This may be a result of ospemifene’s an-
tiestrogen effect in the breast tissue. 
4.1. Limitations 
While administrative claims databases’ ability to facilitate real- 
world safety and efficacy research is unquestioned, these databases do 
present certain limitations. Assessing ospemifene treatment utilization 
as prescribed is a limitation with claims data. MarketScan® provides a 
record of drug dispensing claims; however, it does not provide ad-
herence information, as such, patients prescribed ospemifene may not 
have use it as prescribed, potentially biasing safety results here. 
Certain BC risk or prognostic factors [e.g. age at menarche and 
menopause, parity, family history, prior use of SERMS or AI in a pre-
ventative manner, BC stage at diagnosis (applies only to recurrence 
analysis) and breast atypia] were not available in this data source. As 
such, it was not possible to match patients or balance the cohorts based 
these factors. Further, rationales for recorded interventions were not 
available. It was difficult to ascertain whether mastectomy, used in this 
study as a proxy for BC diagnosis, was done prophylactically, as a 
contralateral prophylactic mastectomy (CPM). However, rates of CPM 
are significantly lower than unilateral mastectomies and would likely 
represent a small proportion of our case population [22]. Furthermore, 
prophylactic procedures would be billed using specific procedure codes 
for CPM, which were not included in our definition of mastectomy. 
Claims databases are subject to possible coding errors, coding for the 
purpose of rule-out rather than actual disease, and under-coding, 
without the possibility of verifying reported diagnoses. Generally, this 
type of non-directional misclassification error should bias to the null 
and therefore make our results more conservative. 
The two-year time horizon may confer additional limitations. 
Studies have shown that BC recurrence in estrogen receptor-positive 
(ER+) BC may have late recurrence [23–25]. However, it is rare that 
recurrence curves would cross over time and therefore it would be 
unexpected to see drastically different results over longer follow-ups. 
Nonetheless, additional studies are warranted to verify that the trends 
remain consistent over longer periods. 
From an analytical perspective, the case-control matched approach 
had limitations. This method aims to mitigate observable risk factors 
and confounding variables that may impact risk of BC incidence and 
recurrence; given the strict matching criteria, where cases were mat-
ched with two controls, the full sample of patients was not fully uti-
lized. 
4.2. Conclusions 
Ospemifene-treated VVA patients did not have a higher incidence of 
breast cancer or breast cancer recurrence than postmenopausal women 
with VVA without any prescribed VVA-related treatment. This analysis 
further supports the findings of prior evidence reporting no increased 
risk for breast cancer-related safety concerns among patients receiving 
ospemifene [14–18,20]. Additional efforts should be made to educate 
both physicians and patients of the safety of ospemifene as a treatment 
option for postmenopausal women with VVA who have had or may be 
at risk for breast cancer. 
Contributors 
Bin Cai conceptualized the study and contributed to the data ana-
lysis, data interpretation, and review and editing of the manuscript. 
James Simon contributed to data interpretation, and review and 
editing of the manuscript. 
Paola Villa contributed to data interpretation, and review and 
editing of the manuscript. 
Nicoletta Biglia contributed to data interpretation, and review and 
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Table 2 
Life table estimate of the risk of breast cancer over 6-month post-treatment follow-up intervals, (a) censoring patients discontinuing treatment and those lost to follow 
and (b) only censoring patients lost to follow-up.         
(a) 
Group Interval Number of patients at the 
beginning of interval 
Number of breast 
cancer diagnoses 
Number of patients 
censored during the interval 





month ends  
Ospemifene-treated 
group 
0 6 months 1728 0 724 1.0000 
6 months 12 months 1004 1 216 1.0000 
12 months 18 months 787 1 229 0.9989 
18 months 24 months 557 1 158 0.9974 
24 months 30 months 398 0 139 0.9953 
30 months 36 months 259 0 98 0.9953 
36 months 42 months 161 0 62 0.9953 
42 months 48 months 99 0 46 0.9953 
48 months 54 months 53 0 31 0.9953 
54 months 60 months 22 0 18 0.9953 
60 months 66 months 4 0 4 0.9953 
66 months . 0 0 0 0.9953 
Untreated group 0 6 months 3456 7 0 1.0000 
6 months 12 months 3449 4 0 0.9980 
12 months 18 months 3445 10 610 0.9968 
18 months 24 months 2825 3 564 0.9936 
24 months 30 months 2258 2 547 0.9925 
30 months 36 months 1709 3 484 0.9915 
36 months 42 months 1222 1 413 0.9894 
42 months 48 months 808 1 324 0.9885 
48 months 54 months 483 1 279 0.9869 
54 months 60 months 203 0 151 0.9841 
60 months 66 months 52 0 46 0.9841 
66 months 72 months 6 0 6 0.9841 
72 months . 0 0 0 0.9841         
(b)      
Group Interval Number of patients at the 
beginning of interval 
Number of breast 
cancer diagnoses 
Number of patients 
censored during the interval 





month ends  
Ospemifene-treated 
group 
0 6 months 1728 0 0 1.0000 
6 months 12 months 1728 1 0 1.0000 
12 months 18 months 1727 4 325 0.9994 
18 months 24 months 1398 2 296 0.9969 
24 months 30 months 1100 1 285 0.9953 
30 months 36 months 814 0 253 0.9942 
36 months 42 months 561 0 189 0.9942 
42 months 48 months 372 1 153 0.9942 
48 months 54 months 218 0 128 0.9909 
54 months 60 months 90 0 70 0.9909 
60 months 66 months 20 0 18 0.9909 
66 months 72 months 2 0 2 0.9909 
72 months  0 0 0 0.9909 
Untreated group 0 6 months 3456 7 0 1.0000 
6 months 12 months 3449 4 0 0.9980 
12 months 18 months 3445 10 610 0.9968 
18 months 24 months 2825 3 564 0.9936 
24 months 30 months 2258 2 547 0.9925 
30 months 36 months 1709 3 484 0.9915 
36 months 42 months 1222 1 413 0.9894 
42 months 48 months 808 1 324 0.9885 
48 months 54 months 483 1 279 0.9869 
54 months 60 months 203 0 151 0.9841 
60 months 66 months 52 0 46 0.9841 
66 months 72 months 6 0 6 0.9841 
72 months  0 0 0 0.9841 
Note: The assessment period was between the first claim date of ospemifene and the last claim date after accounting for days of supply. Continuous treatment duration 
was not considered.  
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